Vectans Pharma is delighted to announce that COFEPRIS has granted Loramyc® Marketing Authorization on Mexican territory.

« We are so glad to achieve this milestone with our partner M8. It’s undoubtedly a new growth opportunity for Loramyc® and an advanced treatment for all Mexican patients suffering from OPC. » said Vectans Pharma’s Director of Regulatory and Industrial Affairs, Jonathan Cohen.